Editorial: New understandings and research in anal squamous cell carcinoma.
作者信息
Kim Stefano, De Bari Berardino, Spehner Laurie
机构信息
Clinical Investigational Center, INSERM CIC-1431, Centre Hospitalier Universitaire de Besançon, Besancon, France.
Department of Oncology, Sanatorio Allende, Cordoba, Argentina.
出版信息
Front Oncol. 2023 Jan 16;12:1131678. doi: 10.3389/fonc.2022.1131678. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: New understandings and research in anal squamous cell carcinoma.社论：肛门鳞状细胞癌的新认识与研究
Front Oncol. 2023 Jan 16;12:1131678. doi: 10.3389/fonc.2022.1131678. eCollection 2022.
2
[Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].[根治性放疗联合不同化疗方案对非转移性肛管鳞状细胞癌患者放射性肠损伤的影响]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Nov 25;24(11):977-983. doi: 10.3760/cma.j.cn441530-20210810-00320.
3
Outcome analysis of HIV-positive patients with anal squamous cell carcinoma.HIV阳性的肛管鳞状细胞癌患者的预后分析
Dis Colon Rectum. 2001 Apr;44(4):506-12. doi: 10.1007/BF02234322.
4
Patterns of Care and Comparison of Outcomes Between Primary Anal Squamous Cell Carcinoma and Anal Adenocarcinoma.原发肛门鳞癌与肛门腺癌的治疗模式和结局比较。
Dis Colon Rectum. 2019 Dec;62(12):1448-1457. doi: 10.1097/DCR.0000000000001506.
5
Anal human papilloma viral infection and squamous cell carcinoma: Need objective biomarkers for risk assessment and surveillance guidelines.肛管人乳头瘤病毒感染与鳞状细胞癌：需要用于风险评估和监测指南的客观生物标志物。
World J Gastrointest Oncol. 2022 Feb 15;14(2):369-374. doi: 10.4251/wjgo.v14.i2.369.
6
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.多西他赛、顺铂和氟尿嘧啶化疗治疗转移性或不可切除的局部复发性肛门鳞状细胞癌（Epitopes-HPV02）：一项多中心、单臂、Ⅱ期研究。
Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.
7
Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy.高效抗逆转录病毒治疗时代，感染人类免疫缺陷病毒的肛管浸润性鳞状细胞癌患者的预后
Dis Colon Rectum. 2004 Aug;47(8):1305-9. doi: 10.1007/s10350-004-0584-1.
8
Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?溃疡性结肠炎相关的肛门鳞癌：是否造口能够耐受传统治疗方案？
Dis Colon Rectum. 2021 Sep 1;64(9):1106-1111. doi: 10.1097/DCR.0000000000002011.
9
An alternative treatment of anal squamous cell carcinoma: combined radiotherapy and chemotherapy.肛管鳞状细胞癌的一种替代治疗方法：放疗与化疗联合应用。
J Surg Oncol. 1993 Jan;52(1):42-5. doi: 10.1002/jso.2930520112.
10
Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy.肛管鳞癌的治疗：抗 EGFR 治疗和免疫治疗的新策略。
Crit Rev Oncol Hematol. 2018 Mar;123:52-56. doi: 10.1016/j.critrevonc.2018.01.007. Epub 2018 Feb 2.
本文引用的文献
1
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).一项评估 INCMGA00012（Retifanlimab）在接受铂类化疗（POD1UM-202）后进展的局部晚期或转移性肛门鳞癌患者中的疗效和安全性的多中心、开放标签、单臂 II 期临床研究。
ESMO Open. 2022 Aug;7(4):100529. doi: 10.1016/j.esmoop.2022.100529. Epub 2022 Jul 8.
2
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.对一线晚期肛管鳞状细胞癌的Epitopes-HPV01和Epitopes-HPV02研究的更新数据中的115例患者进行汇总分析。
Ther Adv Med Oncol. 2020 Dec 4;12:1758835920975356. doi: 10.1177/1758835920975356. eCollection 2020.
3
Anti-Telomerase CD4 Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials.抗端粒酶 CD4 Th1 免疫和单核细胞-髓样来源抑制细胞与多西紫杉醇、顺铂和氟尿嘧啶（DCF）治疗晚期肛门鳞状细胞癌的长期疗效相关：HPV01 和 02 试验的表位研究。
Int J Mol Sci. 2020 Sep 17;21(18):6838. doi: 10.3390/ijms21186838.
4
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.国际罕见癌症倡议多中心随机二期试验：顺铂和氟尿嘧啶对比卡铂和紫杉醇治疗晚期肛门癌：InterAAct。
J Clin Oncol. 2020 Aug 1;38(22):2510-2518. doi: 10.1200/JCO.19.03266. Epub 2020 Jun 12.
5
Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer.确诊性盆部放射治疗与新发转移性肛门癌患者的生存
J Natl Compr Canc Netw. 2019 Jan;17(1):29-37. doi: 10.6004/jnccn.2018.7085.
6
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.多西他赛、顺铂和氟尿嘧啶化疗治疗转移性或不可切除的局部复发性肛门鳞状细胞癌（Epitopes-HPV02）：一项多中心、单臂、Ⅱ期研究。
Lancet Oncol. 2018 Aug;19(8):1094-1106. doi: 10.1016/S1470-2045(18)30321-8. Epub 2018 Jul 2.
7
Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.现代图像引导调强放疗可使肛管癌患者在放化疗中具有低毒性率和良好的局部控制效果。
J Cancer Res Clin Oncol. 2018 Apr;144(4):781-789. doi: 10.1007/s00432-018-2608-6. Epub 2018 Feb 13.
8
Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.基于断层放射治疗的同步放化疗用于局部晚期肛门癌的前瞻性II期研究。
Radiother Oncol. 2015 Nov;117(2):234-9. doi: 10.1016/j.radonc.2015.08.008. Epub 2015 Aug 22.
9
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.全身化疗和多学科管理在改善肛管转移性鳞状细胞癌患者总生存期方面的作用。
Oncotarget. 2014 Nov 30;5(22):11133-42. doi: 10.18632/oncotarget.2563.
10
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.RTOG 0529：评估剂量描绘调强放疗联合氟尿嘧啶和丝裂霉素 C 用于降低肛门管癌急性发病率的 2 期研究。
Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):27-33. doi: 10.1016/j.ijrobp.2012.09.023. Epub 2012 Nov 12.
Zotero 插件